Premium
P2‐411: Cerebrospinal fluid biomarker profile in late‐life depression and association with cognitive impairment
Author(s) -
Luborzewski Alexander,
Schipke Carola,
Friese Alexander,
Buehrsch Nicole,
Haas Brigitte,
Heuser Isabella,
Peters Oliver
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.2036
Subject(s) - depression (economics) , medicine , biomarker , cerebrospinal fluid , neuropsychology , cognitive decline , memory clinic , cognitive impairment , late life depression , oncology , cognition , dementia , memory impairment , disease , gastroenterology , psychology , psychiatry , economics , macroeconomics , biochemistry , chemistry
(MRI) and blood biomarker levels.Results: Plasma BDNF levels were measured in 1112 plasma samples. Preliminary analyses suggest our findings support the hypothesis that BDNF levels are altered in individuals with AD compared to cognitively healthy controls. Further analysis will establish the relationship between plasma BDNF and PiB-PET determined brain amyloid burden.Conclusions:To our knowledge, this study is the first to assess the relationship between brain amyloid burden and BDNF levels. Additional analysis is required to ascertain the suitability of BDNF as a candidate AD blood biomarker. The significance of our findings will be evaluated using longitudinal data from the AIBL study of ageing.